Aerovate Therapeutics, INC Form 4 insider transactions
Marinus Verwijs, Chief Technical Officer of Aerovate Therapeutics, sold shares of common stock and exercised stock options on April 1, 2024, under a pre-arranged 10b5-1 trading plan.
George A. Eldridge, CFO of Aerovate Therapeutics, executed stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.
Hunter Gillies, Chief Medical Officer of Aerovate Therapeutics, exercised stock options and sold shares on March 28, 2024, according to a recent SEC filing.
Benjamin T. Dake, a key officer at Aerovate Therapeutics, executed stock options and sold shares according to a pre-arranged trading plan.
Benjamin T. Dake, an officer at Aerovate Therapeutics, sold 3,432 shares of common stock on March 25, 2024, as part of a pre-arranged trading plan.
Marinus Verwijs, Chief Technical Officer of Aerovate Therapeutics, sold shares of common stock on March 19, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Hunter Gillies, Chief Medical Officer of Aerovate Therapeutics, exercised stock options and sold shares on March 18, 2024, according to a Form 4 filing with the SEC.
Benjamin T. Dake, an officer at Aerovate Therapeutics, reported the acquisition and disposal of common stock and the exercise of stock options on March 18, 2024, according to a Form 4 filing with the SEC.
Form 4: Aerovate Therapeutics CFO George Eldridge Executes Stock Option and Sells Shares Under 10b5-1 Plan
George Eldridge, CFO of Aerovate Therapeutics, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.
Aerovate Therapeutics' CFO, George Eldridge, executed stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.
Hunter Gillies, Chief Medical Officer of Aerovate Therapeutics, executed stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.
Form 4: Aerovate Therapeutics Director, Habib J Dable, Acquires Stock Options in Lieu of Cash Compensation
Habib J Dable, a director of Aerovate Therapeutics, acquired stock options in lieu of cash compensation on March 4, 2024.
Chief Medical Officer Gillies Hunter of Aerovate Therapeutics reports the exercise of stock options and subsequent sale of shares under a pre-arranged trading plan.